SUMMARY
The role of prostaglandin F2α (pgf2α) in embryonic loss following induced endotoxemia was studied in mares that were 21 to 44 days pregnant. Thirteen pregnant mares were treated with a nonsteroidal anti-inflammatory drug, flunixin meglumine, to inhibit the synthesis of pgf2α caused by Salmonella typhimurium endotoxin given iv. Flunixin meglumine was administered either before injection of the endotoxin (group 1, -10 min; n = 7), or after endotoxin injection into the mares (group 2, 1 hour, n = 3; group 3, 2 hours, n = 3); 12 pregnant mares (group 4) were given only S typhimurium endotoxin.
In group 4, the secretion of pgf2α, as determined by plasma 15-keto-13,14-dihydro-pgf2α concentrations, was biphasic, initially peaking at 30 minutes followed by a second, larger peak approximately 105 minutes after the endotoxin was given iv. When flunixin meglumine was administered at −10 minutes, synthesis of pgf2α was inhibited for several hours, after administration of flunixin meglumine at 1 hour, the second secretory surge of pgf2α was blocked, and administration of the drug at 2 hours did not substantially modify the secretion of pgf2α.
Plasma progesterone concentrations were unchanged after endotoxin injections were given in group 1. In group 2, progesterone values decreased < 2 ng/ml and remained low for several days. In group 3 and group 4, progesterone concentrations decreased to values < 0.5 ng/ml by 48 hours after endotoxin injections were given. Pregnancy continued in all 7 mares in group 1; in group 2, pregnancy continued in 2 of 3 mares; and in group 3, none of the 3 mares was pregnant by 4 days after endotoxin administration.
The abortifacient effect of endotoxemia in mares < 2 months pregnant is mediated indirectly through the secretion of pgf2α; compromised luteal activity and inadequate progesterone secretion are the primary causes of fetal death. Although flunixin meglumine administration can be used to prevent loss of pregnancy in cases of endotoxemia, it must be initiated at an early stage of the endotoxemia, that is, when clinical signs are often not yet apparent.
